DRG Disease Intelligence & Analytics
See where a disease market is headed — before others do.
Expert‑curated disease, epidemiology, and treatment insights to help pharma teams size opportunity, validate assumptions, and plan with confidence.
Why disease strategy is harder than it used to be:
- Innovation and new modalities are rapidly reshaping treatment pathways
- Biosimilars and generics are disrupting historical forecasts
- Patient populations are more segmented and complex
- Real‑world treatment behavior doesn’t always match expectations
- Critical data is fragmented across disconnected sources
When you don’t have the full story, forecasting, prioritization, and strategic alignment become harder — and competitors move faster.
Request more information
See the full story of a disease
DRG Disease Intelligence & Analytics brings disease epidemiology, treatment dynamics, competitive context, and expert analysis together—so teams can move from assumptions to confident decisions.
Be empowered to:
Why DRG Disease Intelligence & Analytics?
Expert‑built disease insight, gold‑standard epidemiology, and integrated real‑world intelligence — all grounded in transparent, defensible methodology trusted by leading pharma teams.
- Deep therapy-area expertise: Built and curated by 100+ team of expert analysts, therapy-area specialists, pharmacists, and 40+ team of epidemiologists
- Gold-standard epidemiology & forecasting: Industry‑leading incidence and prevalence models with rigorous, transparent methodology and 10–20‑year forecasts across 240+ indications and thousands of segments, with global coverage.
- Integrated, multi-source intelligence: Disease epidemiology, treatment dynamics, real‑world claims, physician insights, and unmet‑need analysis are brought together into a coherent, decision‑ready view — reducing reliance on fragmented sources and manual synthesis.
- Indication‑level depth across prevalent and rare diseases: Granular population segmentation, unmet‑need analysis, and emerging therapy outlooks — designed for fast‑evolving, high‑complexity therapeutic areas.
- Trusted, transparent methodology: Clear assumptions, validated models, and expert‑curated analysis give commercial, clinical, and R&D teams a shared foundation they can trust.
